COMPANY

SciNeuro Pharmaceuticals

HQ: Rockville, MD source · scineuro.com ↗ · Mid-Atlantic

Keywords: neurology neurodegenerative diseases Diabetic Macular Edema DME Alzheimer's Disease Parkinson's Disease Multiple System Atrophy SNP318 SNP318 (A)

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Raises and deals from press releases

Deal Novartis deal · amount not disclosed · announced Jan 12, 2026 Company release ↗
Source quote
- Jan 12, 2026 · Company release ↗
  “SciNeuro grants Novartis an exclusive worldwide license to develop SciNeuro’s novel antibody program that leverages a proprietary shuttle technology to enhance brain delivery of therapeutic agents to treat Alzheimer’s Disease SciNeuro and Novartis will collaborate during early development”
Raise Undisclosed round · $53M · announced Dec 4, 2025 Company release ↗
Source quote
- Dec 4, 2025 · Company release ↗
  “SciNeuro Pharmaceuticals (“ SciNeuro ”), a biotech company pioneering the development of novel treatments for neurodegenerative diseases, today announced the completion of a total of $53 million in equity financing”

Raises announced in these releases: $53M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Dec 4, 2025 Raise Undisclosed round · $53M source ↗
Mar 20, 2023 Trial start Phase 1: A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease source ↗
Nov 23, 2021 Trial start —: An Observational Study of Parkinson's Disease and Other Synucleinopathies (EASE-PD) source ↗
2025-11 Trial start 2: A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients source ↗

Upcoming milestones

2026-11 (ESTIMATED) · 2 · A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients · NCT07199777

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07199777	A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients	2	Not yet recruiting	2025-11	2026-11 (estimated)
NCT05792163	A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease	Phase 1	Completed	Mar 20, 2023	Nov 29, 2023 (actual)
NCT05638815	An Observational Study of Parkinson's Disease and Other Synucleinopathies (EASE-PD)	Not listed	Completed	Nov 23, 2021	Jul 10, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗